ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0698

Baseline Factors Are Not Associated with Rehabilitation Dose over Six Months Among Adults with RA

Orthopedics, Low Back Pain, & Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 0906

Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0859

Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0669

Calcium Pyrophosphate Crystal Deposition in Gouty Tophi

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0922

Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0740

Card9 Promotes Th17-mediated Arthritis and Spondylitis via Control of Acute Pathogenic Neutrophil Responses in SKG Mice

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0927

Care Gap in Patients with Systemic Sclerosis with CXR Findings Suggestive of Fibrosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 0662

Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0841

CD6 Modulation Ameliorates Kidney and Skin Disease in a Spontaneous Murine Lupus Model

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0610

Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0652

Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0732

Changing Evidence over Time: Updated Meta-analysis Regarding Anti-TNF Efficacy in Childhood Chronic Uveitis

Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: Abstract Number: 0903

Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Arthritis: An Analysis of the OPAL Dataset

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0523

Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 0533

Characterization of Older Male Patients with a Fragility Fracture

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].